Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Massachusetts-based pharmaceutical company Sepracor has exclusively licensed US rights for its levocetirizine allergy treatment to Belgian biopharmaceutical firm UCB.
Subscribe to our email newsletter
All of Sepracor’s patents and patent applications in the US regarding the antihistamine are now licensed to UCB, who will have to pay royalties to Sepracor on US sales of levocetirizine products.
Under a separate agreement, Sepracor currently earns royalties from UCB on sales of levocetirizine in European countries where the product is sold. Levocetirizine is marketed by UCB under the brand names Xyzal and Xusal in the Europe for treatment of symptoms of seasonal and perennial allergic rhinitis, persistent allergic rhinitis, and chronic idiopathic urticaria in adults and children aged 6 years and older.
“UCB has built a successful antihistamine franchise worldwide and we are optimistic about the opportunity UCB has to expand it with the introduction of levocetirizine in the US,” said Timothy Barberich, chairman and CEO of Sepracor.